←
Mark Morgan's Lab216 posts
Mark Morgan's Lab avatar

Mark Morgan's Lab

@M_MorganLab

Receptor Dynamics in Cancer Laboratory / Institute of Systems, Molecular & Systems Biology / University of Liverpool, UK

◷ Joined September 2013▧ 13 Photos and videos
Mark Morgan's Lab avatar
Mark Morgan's Lab@M_MorganLab·5 Dec 2024

Very excited to share our latest paper describing crosstalk between αvβ6 integrin & HER2 in breast cancer invasion & drug resistance. Great work by @HJMald & many others science.org/doi/10.1126/scia… @ScienceAdvances @LivUniISMIB @AdamHurlstone Many thanks to @BCCare @NorthWestCancer

Mark Morgan's Lab avatar
Mark Morgan's Lab@M_MorganLab·5 Dec 2024

6) High levels of GDI2 expression correlate with better patient survival 7) Levels of αVβ6 expression at initial diagnosis predict disease relapse following trastuzumab treatment

Mark Morgan's Lab avatar
Mark Morgan's Lab@M_MorganLab·5 Dec 2024

6) High levels of GDI2 expression correlate with better patient survival 7) Levels of αVβ6 expression at initial diagnosis predict disease relapse following trastuzumab treatment

Mark Morgan's Lab avatar
Mark Morgan's Lab@M_MorganLab·5 Dec 2024

A particularly intriguing observation: Invasion of trastuzumab resistant cells is αVβ6-independent. But resistant cells express very high levels αVβ6 on the cell surface. Opening up opportunities to potentially target them with an αVβ6-targeting warhead, or immuno-modulator

Mark Morgan's Lab avatar
Mark Morgan's Lab@M_MorganLab·5 Dec 2024

5) Components of the trafficking regulatory subnetwork are highly expressed in HER2+ breast cancers expressing high levels of αVβ6.

Mark Morgan's Lab avatar
Mark Morgan's Lab@M_MorganLab·5 Dec 2024

4) RAB5, RAB7A, and GDI2 differentially regulate invasion and αVβ6 integrin-mediated TGFβ activation, but this mechanism is uncoupled by trastuzumab resistance, rendering cells unresponsive to αVβ6, HER2 or TGFβ-Receptor inhibition.

Mark Morgan's Lab avatar
Mark Morgan's Lab@M_MorganLab·5 Dec 2024

2) Components of the trafficking regulatory subnetwork mediate direct crosstalk between αVβ6 and HER2, affecting receptor trafficking and signalling. 3) Trastuzumab resistance disrupts αVβ6-mediated control of HER2 endocytosis and signalling.

Mark Morgan's Lab avatar
Mark Morgan's Lab@M_MorganLab·5 Dec 2024

We show that: 1) Integrin αVβ6 recruits HER2 and a RAB5/RAB7A/GDI2 trafficking regulatory subnetwork. This recruitment is enhanced by exposure to the HER2-trageting drug trastuzumab, but dysregulated following acquired trastuzumab resistance

Mark Morgan's Lab avatar
Mark Morgan's Lab@M_MorganLab·5 Dec 2024

5) Components of the trafficking regulatory subnetwork are highly expressed in HER2+ breast cancers expressing high levels of αVβ6.

Mark Morgan's Lab avatar
Mark Morgan's Lab@M_MorganLab·5 Dec 2024

4) RAB5, RAB7A, and GDI2 differentially regulate invasion and αVβ6 integrin-mediated TGFβ activation, but this mechanism is uncoupled by trastuzumab resistance, rendering cells unresponsive to αVβ6, HER2 or TGFβ-Receptor inhibition.

Mark Morgan's Lab avatar
Mark Morgan's Lab@M_MorganLab·5 Dec 2024

2) Components of the trafficking regulatory subnetwork mediate direct crosstalk between αVβ6 and HER2, affecting receptor trafficking and signalling. 3) Trastuzumab resistance disrupts αVβ6-mediated control of HER2 endocytosis and signalling.

Mark Morgan's Lab avatar
Mark Morgan's Lab@M_MorganLab·5 Dec 2024

We show that: 1) Integrin αVβ6 recruits HER2 and a RAB5/RAB7A/GDI2 trafficking regulatory subnetwork. This recruitment is enhanced by exposure to the HER2-trageting drug trastuzumab, but dysregulated following acquired trastuzumab resistance.